Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia

Albert Deisseroth, Ann Farrell, Robert Justice, Robert Kane, Rajeshwari Sridhara, Huanyu Chen, Kun He, Richard Pazdur

Blood (2010) 115 (2): 430.

https://doi.org/10.1182/blood-2009-09-244236

Published: 2010

Journal Articles

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse

Francis Giles, Norbert Vey, Daniel DeAngelo, Karen Seiter, Wendy Stock, Robert Stuart, Darinka Boskovic, Arnaud Pigneux, Martin Tallman, Joseph Brandwein, Jonathan Kell, Tadeusz Robak, Peter Staib, Xavier Thomas, Ann Cahill, Maher Albitar, Susan O'Brien

Blood (2009) 114 (19): 4027–4033.

https://doi.org/10.1182/blood-2009-06-229351

Published: 2009

Journal Articles

Hypermethylation of O 6 -Methylguanine-DNA Methyltransferase (MGMT) Predicts Response to Laromustine (Cloretazine®) in Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Ilan Bernstein, MD, Francis Giles, MD, Susan O’Brien, MD, Elizabeth Sullivan, MS, Norbert Vey, MD, Allen S. Yang, MD, PhD

Blood (2008) 112 (11): 4463.

https://doi.org/10.1182/blood.V112.11.4463.4463

Published: 2008

Journal Articles

A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Cloretazine®) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial

Robert Hills, MA, MSc, DPhil, Susan O’Brien, M.D., Verena Karsten, PhD, Alan K. Burnett, MD, FRCP, Francis Giles, MD

Blood (2008) 112 (11): 2960.

https://doi.org/10.1182/blood.V112.11.2960.2960

Published: 2008

Journal Articles

Survival after Complete Response to Treatment with Laromustine (CLORETAZINE ® ) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML).

Susan O’Brien, M.D., Gary Schiller, Robert Kenneth Stuart, MD, Diana Hudak, Francis Giles, MD

Blood (2008) 112 (11): 940.

https://doi.org/10.1182/blood.V112.11.940.940

Published: 2008

Journal Articles

A Double Blind Placebo-Controlled Randomized Phase III Study of High Dose Continuous Infusion Cytosine Arabinoside (araC) with or without Cloretazine® in Patients with First Relapse of Acute Myeloid Leukemia (AML).

Francis J. Giles, Wendy Stock, Norbert Vey, Karen Seiter, Daniel J. DeAngelo, Darinka Boskovic, Robert K. Stuart, Bonny Johnson, Ann L. Cahill, Susan O’Brien

Blood (2006) 108 (11): 1970.

https://doi.org/10.1182/blood.V108.11.1970.1970

Published: 2006

Journal Articles

A Phase I Study of Cloretazine® and Temozolomide in Patients with Hematologic Malignancies.

David A. Rizzieri, William Tse, Khuda D. Khan, Anjali Advani, Jon Donze, Verena Karsten, Robert B. Geller, Stanton L. Gerson

Blood (2006) 108 (11): 1971.

https://doi.org/10.1182/blood.V108.11.1971.1971

Published: 2006

Journal Articles

Antiproliferative Activity of ELACYT™ (CP-4055) in Combination with Cloretazine (VNP40101M), Idarubicin or Gemcitabine in HL-60 Human Myeloid Leukemia Cells.

David J. Adams, PhD, Marit L. Sandvold, PhD, Fynn Myhren, PhD, Tove F. Jacobsen, PhD, David A. Rizzieri, MD

Blood (2006) 108 (11): 1991.

https://doi.org/10.1182/blood.V108.11.1991.1991

Published: 2006

Journal Articles

Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Targeted Therapy May Benefit from Prophylactic Measures Against Infections.

Gloria N. Mattiuzzi, MD, Jorge E. Cortes, MD, Stefan Faderl, MD, Maria E. Cabanillas, MD, Francis J. Giles, MD, Susan O’Brien, MD, Guillermo Garcia-Manero, MD, Hagop H. Kantarjian, MD

Blood (2006) 108 (11): 4483.

https://doi.org/10.1182/blood.V108.11.4483.4483

Published: 2006

Journal Articles

CLORETAZINE™ (VNP40101M) Is Active in Elderly Untreated Poor Risk Patients with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS).

Francis Giles, MD, Susan O’Brien, MD, David Rizzieri, MD, Judith Karp, MD, Maureen Cooper, MD, Ghulam Mufti, MD, Bonny Johnson, MSN, Verena Karsten, PhD, Norbert Vey, MD

Blood (2005) 106 (11): 2786.

https://doi.org/10.1182/blood.V106.11.2786.2786

Published: 2005

Journal Articles

Use of a Disease-Specific Comorbidity Index To Describe Elderly Patients with Acute Myelogenous Leukemia (AML) and High Risk Myelodysplasia (MDS) Enrolled in a Phase II Study of CLORETAZINE™ (VNP40101M).

Francis Giles, MD, David Rizzieri, MD, Judith Karp, MD, Norbert Vey, MD, Khuda Khan, MD, Ghulam Mufti, MD, Diana Hudak, Verena Karsten, PhD, Susan O’Brien, MD

Blood (2005) 106 (11): 2787.

https://doi.org/10.1182/blood.V106.11.2787.2787

Published: 2005

NARROW

Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse

Hypermethylation of O 6 -Methylguanine-DNA Methyltransferase (MGMT) Predicts Response to Laromustine (Cloretazine®) in Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Cloretazine®) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial

Survival after Complete Response to Treatment with Laromustine (CLORETAZINE ® ) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML).

A Double Blind Placebo-Controlled Randomized Phase III Study of High Dose Continuous Infusion Cytosine Arabinoside (araC) with or without Cloretazine® in Patients with First Relapse of Acute Myeloid Leukemia (AML).

A Phase I Study of Cloretazine® and Temozolomide in Patients with Hematologic Malignancies.

Antiproliferative Activity of ELACYT™ (CP-4055) in Combination with Cloretazine (VNP40101M), Idarubicin or Gemcitabine in HL-60 Human Myeloid Leukemia Cells.

Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Targeted Therapy May Benefit from Prophylactic Measures Against Infections.

CLORETAZINE™ (VNP40101M) Is Active in Elderly Untreated Poor Risk Patients with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS).

Use of a Disease-Specific Comorbidity Index To Describe Elderly Patients with Acute Myelogenous Leukemia (AML) and High Risk Myelodysplasia (MDS) Enrolled in a Phase II Study of CLORETAZINE™ (VNP40101M).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only